Abstract:
A supporter includes a body section having a back-contact section, a first auxiliary band section of which one end is fixed to the top end of a left side of the back-contact section and the other end is fixed to the bottom end of a right side of the back-contact section, a second auxiliary band section forming a pair with the first auxiliary band section, a first ring arranged to slide between the one end and the other end of the first auxiliary band section, a second ring forming a pair with the first ring, a first adjustment band section of which one end is fixed to loops on a right end side of the body section and the other end can be fastened to loops on the right end side of the body section, and a second adjustment band section forming a pair with the first adjustment band section.
Abstract:
Provided is a compound useful in the prevention and treatment of non-alcoholic steatohepatitis. A prophylactic and/or therapeutic agent for non-alcoholic steatohepatitis which contains, as the active ingredient, 2-[4-[2-(benzimidazol-2-ylthio)ethyl]piperazin-1-yl]-N-[2,4-bis(methylthio)-6-methyl-3-pyridyl]acetamide, an acid-addition salt thereof, or a solvate of the same.
Abstract:
The present invention offers novel cyclic diamine compounds and a pharmaceutical composition containing the same. The present invention relates to a compound represented by the formula (I) or salt(s) or solvate(s) thereof. 1 (In the formula, 2 is an optionally substituted divalent residue of benzene, pyridine, cyclohexane or naphthalene or is a vinylene group where Ar is an optionally substituted aryl group; X is nullNHnull, oxygen atom or sulfur atom; Y is nullNR1null, oxygen atom, sulfur atom, sulfoxide or sulfone; Z is a single bond or nullNR2null; R1 is hydrogen atom, optionally substituted lower alkyl group, optionally substituted aryl group or optionally substituted silyl lower alkyl group; R2 is hydrogen atom, optionally substituted lower alkyl group, optionally substituted aryl group or optionally substituted silyl lower alkyl group; l is an integer of from 0 to 15; m is an integer of 2 or 3; and n is an integer of from 0 to 3). The compound of the present invention is useful as a pharmaceutical composition, particuarly as an inhibitor of acyl coenzyme A cholesterol acyltransferase (ACAT).
Abstract translation:本发明提供新的环状二胺化合物和含有它们的药物组合物。 本发明涉及由式(I)表示的化合物或其盐或溶剂化物。 (式中,是苯,吡啶,环己烷或萘的任意取代的二价残基,或者是亚乙烯基,其中Ar是任意取代的芳基; X是-NH-,氧原子或硫原子; Y是-NR1- ,氧原子,硫原子,亚砜或砜; Z是单键或-NR2-; R 1是氢原子,任选取代的低级烷基,任选取代的芳基或任选取代的甲硅烷基低级烷基; R 2是氢原子, 取代的低级烷基,任选取代的芳基或任选取代的甲硅烷基低级烷基; l为0至15的整数; m为2或3的整数; n为0至3的整数)。 本发明的化合物可用作药物组合物,特别是作为酰基辅酶A胆固醇酰基转移酶(ACAT)的抑制剂。
Abstract:
Provided is a non-statutory computer-readable medium storing thereon a medical program for implementing various kinds of processing in a terminal device used together with a medical examination device including an imaging camera, in order to play a video live and record the video, while maintaining usability of the medical examination device including the imaging camera, the video being generated by imaging by the medical examination device. The medical program, when executed, causes a processor of the terminal device to perform: playing video data live and displaying the video data on a display unit of the terminal device, the video data being captured and simultaneously transmitted in real time by the medical examination device; and controlling start/stop of recording of the video data that is currently played live based on a predetermined operation.
Abstract:
Pemafibrate, tofogliflozin, or combinations thereof for use in treating human patients with liver diseases, particularly NASH patients suffering from liver stiffness or liver fibrosis, NASH patients with lobular inflammation, NASH patients with elevated LDL-C, and NASH patients with healthy triglyceride levels.
Abstract:
To provide a medicament for safely treating a patient in need of treatment with pemafibrate, a salt thereof, or a solvate of any of these (hereinafter also referred to as pemafibrate therapy). A medicament for treating a patient in need of pemafibrate therapy, the medicament comprising the step of avoiding or suspending concomitant use of pemafibrate, a salt thereof, or a solvate of any of these as an active ingredient in order to suppress an increase in plasma concentration of pemafibrate when the treatment is combined with a medicament containing an OATP1B inhibitor, or the step of reducing the dose of pemafibrate, a salt thereof, or a solvate of any of these.
Abstract:
The present invention addresses the problem of providing a pharmaceutical composition/drug combination which makes it possible to prevent and/or treat dyslipidemia such as hypercholesterolemia and hypertriglyceridemia, or cardiovascular diseases such as arteriosclerosis and cardiovascular events. The present invention provides a combination of a peroxisome proliferator-activated receptor (PPAR) α agonist and an ATP citrate lyase (ACL) inhibitor for preventing and/or treating dyslipidemia such as hypercholesterolemia and hypertriglyceridemia, or cardiovascular diseases such as arteriosclerosis and cardiovascular events.
Abstract:
To provide a medicament for safely treating a patient in need of treatment with pemafibrate, a salt thereof, or a solvate of any of these (hereinafter also referred to as pemafibrate therapy). A medicament for treating a patient in need of pemafibrate therapy, the medicament comprising the step of avoiding or suspending concomitant use of pemafibrate, a salt thereof, or a solvate of any of these as an active ingredient in order to suppress an increase in plasma concentration of pemafibrate when the treatment is combined with a medicament containing an OATP1B inhibitor, or the step of reducing the dose of pemafibrate, a salt thereof, or a solvate of any of these.
Abstract:
Multiplexer (100) according to the present invention includes: an input unit (11) to which a plurality of image signals based on a first data communication standard are input, the image signals being acquired by respective imaging devices (2); an output unit (14) that outputs an image signal based on a second data communication standard having a data transfer rate lower than that of the first data communication standard; and a storage unit (12) that temporarily buffers the image signals input from the input unit (11). With such a multiplexer 100, it is possible to collectively convert the image data acquired by a plurality of imaging devices adopting a certain data communication standard into another data communication standard and suppress the data transfer delay caused by the conversion.
Abstract:
1. Telescope 2. Telescope 1.1 : Perspective view 1 1.2 : Perspective view 2 1.3 : Front 1.4 : Back 1.5 : Right 1.6 : Top 1.7 : Bottom 1.8 : Left 2.1 : Perspective view 1 2.2 : Perspective view 2 2.3 : Front 2.4 : Back 2.5 : Right 2.6 : Top 2.7 : Bottom 2.8 : Left The broken lines shown in the drawings depict portions of the telescope that form no part of the claimed design.